Clinical Trials Logo

CTLA4 Haploinsufficiency clinical trials

View clinical trials related to CTLA4 Haploinsufficiency.

Filter by:
  • None
  • Page 1

NCT ID: NCT05235438 Recruiting - Oncology Clinical Trials

Safety and Toxicity Study of IMM27M in Patients With Advanced Solid Tumor

Start date: June 15, 2022
Phase: Phase 1
Study type: Interventional

This is a single arm, open label, multi-center and fist in human dose escalation study, to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity in patients with advanced and metastatic solid tumor.

NCT ID: NCT05040256 Completed - Clinical trials for CTLA4 Haploinsufficiency

Neurologic and Immunologic Characteristics of CTLA-4 and LRBA Hereditary Deficiency

Start date: February 1, 2021
Phase:
Study type: Observational

CTLA4 and LRBA deficiencies are rare genetic disorders, recently described, and associated with multiple clinical features. It ranges from recurrent infections, auto-immunity, and organ infiltration with lymphocytes. Neurologic syndroms are described in up to 30% of patients, yet they are poorly defined to date. Early recognition of a specific pattern can be important, given that there is a targeted therapy in this situation.

NCT ID: NCT04377867 Recruiting - Clinical trials for CTLA4 Haploinsufficiency

New Biomarkers for Diagnosis and Follow-up of Patients With LRBA or CTLA4 Deficiencies

Start date: January 15, 2020
Phase:
Study type: Observational [Patient Registry]

Primary immune deficiencies (PID) are a group of chronic diseases characterized by recurrent infections. Apart from recurrent infections, in some of PIDs autoimmunity, allergy or malignancy could be accompanied to the diseases. Recently, the advanced sequencing technologies have led to the identification of a growing number of novel PIDs including the immune dysregulation syndromes caused by loss of function mutations in the LRBA (encoding lipopolysaccharide-responsive beige like anchor protein) and CTLA4 (encoding cytotoxic T lymphocyte antigen 4) genes, which are in common associated with autoimmunity in addition to a predisposition to recurrent infections. PIDs with autoimmune components usually tend to have a more protracted clinical course and poorer prognosis rendering early diagnosis and treatment more crucial. The accurate diagnosis largely relies on the molecular diagnosis due to the significant overlaps between the phenotypic expression of these various genetic defects. The project aims to provide better and early diagnosis for LRBA, CTLA4 deficiencies by using basic and advanced immunological, genetic and molecular assays and rendering an early targeting therapy for patients, discover disease related new pathways and biomarkers that can be helpful during diagnosis and monitoring abatacept targeted therapy responses.